The monoclonal antibody trastuzumab has provided a critical directed therapy that has dramatically improved the prognosis of 20-25% of breast cancer patients whose tumor overexpresses the HER2-neu receptor [2]. The gene discussed is ERBB2; the disease is breast cancer.